Foundation Medicine, Eisai Ink Personalized Med Alliance | GenomeWeb

NEW YORK (GenomeWeb News) – Foundation Medicine today said that it has signed a multi-year alliance with Eisai to conduct genomic profiling and diagnostic discovery for an oncology therapeutic candidate being developed by the Japanese drug firm.

The Cambridge, Mass.-based firm said that the goal of the collaboration is to prospectively identify specific genomic alterations in each patient's tumor. The results would be used for patient stratification, for guiding further drug development, and potentially for the commercialization of molecular diagnostic products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.